A new approach to drug delivery, one that promises to tackle some of the most pressing global healthcare challenges, just got a financial boost. Paralos Bioscience Inc., the biotechnology company behind a first-in-class phage-drug conjugate platform technology, has successfully closed a seed round, raising $647K.
The fresh capital is earmarked to accelerate the development of its innovative drug delivery system. Paralos Bioscience's unique platform aims to enhance the efficacy and precision of treatments, marking an early but significant step for the company in the competitive biotech landscape.
